ImmunoGen, Inc. Appoints Suzanne Cadden as Vice President, Regulatory Affairs & Quality
December 17 2009 - 3:01PM
Business Wire
ImmunoGen, Inc. (Nasdaq:
IMGN), a biotechnology company that develops targeted anticancer
products, announced today the appointment of Suzanne Cadden as Vice
President of Regulatory Affairs & Quality. Ms. Cadden will
be responsible for establishing – in conjunction with the Chief
Medical Officer – the registration strategy for the Company’s
product candidates, for directing the development of regulatory
submissions prepared by ImmunoGen in support of its own programs
and those of its partners, and for managing the Company’s
manufacturing-associated quality functions. Ms. Cadden reports to
Daniel Junius, ImmunoGen President and Chief Executive Officer.
“Suzanne brings to ImmunoGen extensive regulatory experience –
both with the FDA and with international agencies – that we expect
will be highly beneficial to our advancement of our own product
candidates and our support of partner programs,” commented Daniel
Junius. “Further, I believe that as a member of our senior
management team, Suzanne will play an important role in our taking
ImmunoGen to the next level.”
Ms. Cadden brings to ImmunoGen over 20 years of experience
gained at both pharmaceutical and biotechnology companies. Prior to
joining ImmunoGen, she was Vice President of Regulatory Affairs
& Clinical Development at Sierra Neuropharmaceuticals Inc.,
where she was responsible for developing global regulatory and
clinical strategies for novel therapeutics with a focus on the US
and Europe. Before that, she was Vice President of Regulatory
Affairs & Clinical Operations at ActivBiotics Inc. in
Boston, MA, where she oversaw the development of global
regulatory/clinical strategies, including Phase II and III clinical
programs. Before joining ActivBiotics Inc., Ms. Cadden held senior
positions at Transition Therapeutics, LORUS Therapeutics, Glaxo
Wellcome, Inc. and CIBA, Canada. Ms. Cadden has published in
her areas of expertise and holds a M.Sc. in Pharmacology from the
University of Western Ontario and a B.Sc. in Biochemistry &
Nutrition from the University of Guelph.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
its expertise in cancer biology, monoclonal antibodies and the
creation and attachment of potent cell-killing agents. The
Company’s Targeted Antibody Payload (TAP) technology uses
antibodies to deliver one of ImmunoGen’s proprietary cell-killing
agents specifically to cancer targets. In addition to the Company’s
product pipeline, compounds utilizing the TAP technology are in
clinical testing through ImmunoGen’s collaborations with Genentech
(a wholly-owned member of the Roche Group), sanofi-aventis, Biogen
Idec and Biotest. The most advanced compound, trastuzumab-DM1
(T-DM1), is in Phase III testing being conducted by Genentech
and Roche. Other ImmunoGen collaborative partners include Bayer
HealthCare and Amgen. More information about ImmunoGen can be found
at www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024